PR Newswire Clinical TrialsOriginal article
Jubilant Therapeutics Announces First Preliminary Clinical Data from Ongoing Phase 1/2 Study of JBI-802 in Patients with Myeloproliferative Neoplasms at SOHO 2026
Phase 1positiveJBI-802Positive
AI Analysis
Summary
Jubilant Therapeutics announced positive preliminary Phase 1/2 data for JBI-802, a dual LSD1/HDAC6 inhibitor, showing rapid and sustained dose-responsive reductions in platelet counts in patients with essential thrombocythemia and consistent activity in polycythemia vera and other myeloproliferative neoplasms.
Clinical Trial Data
Phase
1/2
Primary Endpoint
Met
Outcome Details
Dual LSD1/HDAC6 inhibitor achieved rapid and sustained dose-responsive reductions in platelet counts in patients with essential thrombocythemia, with consistent activity also observed in polycythemia vera and other conditions
Importance:6/10
Sentiment:
0.70
Phase 1/2 datamyeloproliferative neoplasmsessential thrombocythemiapolycythemia veraLSD1 inhibitorHDAC6 inhibitorSOHO 2026 conference
Read the original article
Published by PR Newswire Clinical Trials on September 15, 2026 1:32 PM